Rituximab in Primary Central Nervous system Lymphoma. A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study

DOI number 10.58109/jazm-1d71
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Samar Issa (North Middlemore Hospital)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes

  • Data for 45 patients with newly diagnosed Primary Central Nervous System Lymphoma (PCNSL) assessing the addition of rituxumab vs standard chemotherapy
  • Demographic data
  • Diagnostic, data
  • Treatment data
  • Outcome data
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)
ANZCTR Reference ACTRN12610000908033
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
NHL21
NHL26